Cargando…
Protocol for production and purification of SARS-CoV-2 3CL(pro)
3CL(pro) protease from SARS-CoV-2 is a primary target for COVID-19 antiviral drug development. Here, we present a protocol for 3CL(pro) production in Escherichia coli. We describe steps to purify 3CL(pro), expressed as a fusion with the Saccharomyces cerevisiae SUMO protein, with yields up to 120 mg...
Autores principales: | Mazzei, Luca, Greene-Cramer, Rebecca, Bafna, Khushboo, Jovanovic, Aleksandar, De Falco, Anna, Acton, Thomas B., Royer, Catherine Ann, Ciurli, Stefano, Montelione, Gaetano T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160526/ https://www.ncbi.nlm.nih.gov/pubmed/37235475 http://dx.doi.org/10.1016/j.xpro.2023.102326 |
Ejemplares similares
-
Structural similarities between SARS-CoV2 3CL(pro) and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals
por: Bafna, Khushboo, et al.
Publicado: (2022) -
Structural Similarity of SARS-CoV2 M(pro) and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics
por: Bafna, Khushboo, et al.
Publicado: (2020) -
Structure function characterization of SARS CoV2 proteases for COVID19 antiviral development
por: Greene-Cramer, Rebecca, et al.
Publicado: (2022) -
Hepatitis C Virus Protease Inhibitors Suppress Virus Replication and Act Synergistically with the SARS-CoV2 Polymerase Inhibitor Remdesivir
por: Bafna, Khushboo, et al.
Publicado: (2021) -
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
por: Bafna, Khushboo, et al.
Publicado: (2021)